S3 Guideline Urticaria. Part 2: Treatment of urticaria – German‐language adaptation of the international S3 guideline
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2023
DOI: 10.1111/ddg.14932 ↗Kurz gefasst
Leitlinie in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2023. Verfasst von Torsten Zuberbier und 19 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berl…. Hauptthemen laut MEDLINE: Urticaria, Chronic Urticaria, Histamine H1 Antagonists, Non-Sedating. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
This publication is the second part of the German‐language S3 guideline on urticaria. It covers the management of urticaria and should be used together with Part 1 of the guideline on classification and diagnosis. This publication was prepared according to the criteria of the AWMF on the basis of the international English‐language S3 guideline with special consideration of health system conditions in German‐speaking countries. Chronic urticaria has a high impact on the quality of life and daily activities of patients. Therefore, if causal factors cannot be eliminated, effective symptomatic treatment is necessary. The recommended first‐line treatment is to administer new generation, non‐sedating H1 antihistamines. If the standard dose is not sufficiently effective, the dose should be increased up to fourfold. For patients who do not respond to this treatment, the second‐line treatment in addition to antihistamines in the treatment algorithm is omalizumab and, if this treatment fails, ciclosporin. Other low‐evidence therapeutic agents should only be used if all treatments in the treatment algorithm agreed upon by the guideline group fail. Both the benefit‐risk profile and cost should be considered. Corticosteroids are not recommended for long‐term treatment due to their inevitable severe side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
- University Hospital for Dermatology und Venereology, Comprehensive Allergy Center, Kepler University Hospital, Linz, Austria.
- Urtikaria-Helden e.V., Koblenz, Germany.
- Center for Skin Diseases, University Hospital Münster, Department of Dermatology, Münster, Germany.
- Department and Clinic for Dermatology und Allergology am Biederstein, Technical University of Munich, Munich, Germany.
Zitieren
APA
Zuberbier, T., Altrichter, S., Bauer, S., Brehler, R., Brockow, K., Dressler, C., Fluhr, J., Gaskins, M., Hamelmann, E., Kühne, K., Merk, H., Mülleneisen, N. K., Nast, A., Olze, H., Ott, H., Pleimes, M., Ruëff, F., Staubach-Renz, P., Wedi, B., & Maurer, M. (2023). S3 Guideline Urticaria. Part 2: Treatment of urticaria – German‐language adaptation of the international S3 guideline. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.14932
Vancouver
Zuberbier T, Altrichter S, Bauer S, Brehler R, Brockow K, Dressler C, et al. S3 Guideline Urticaria. Part 2: Treatment of urticaria – German‐language adaptation of the international S3 guideline. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2023. doi:10.1111/ddg.14932
BibTeX
@article{Zuberbier2023,
author = {Zuberbier, Torsten and Altrichter, Sabine and Bauer, Sabine and Brehler, Randolf and Brockow, Knut and Dressler, Corinna and Fluhr, Joachim and Gaskins, Matthew and Hamelmann, Eckard and Kühne, Kathrin and Merk, Hans and Mülleneisen, Norbert K and Nast, Alexander and Olze, Heidi and Ott, Hagen and Pleimes, Marc and Ruëff, Franziska and Staubach-Renz, Petra and Wedi, Bettina and Maurer, Marcus},
title = {S3 Guideline Urticaria. Part 2: Treatment of urticaria – German‐language adaptation of the international S3 guideline},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2023},
doi = {10.1111/ddg.14932}
}
EUVIMED